Testing atacicept for multiple kidney diseases
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a medicine called atacicept in adults and children with several types of kidney disease. The goal is to see if it can reduce protein in the urine and help protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must weigh at least 40 kg (about 88 lbs).
- You must have one of these kidney diseases: IgA nephropathy, IgA vasculitis with kidney involvement, primary membranous nephropathy, minimal change disease, focal segmental glomerulosclerosis, or primary nephrotic syndrome.
- Your blood pressure should be controlled (top number 160 or lower, bottom number 90 or lower).
- You need to be on a stable standard treatment plan for your kidney disease.
- You must not have an active viral or bacterial infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called FXS6837 for people with IgA nephropathy, a kidney disease. It aims to see if the drug can help protect kidney function. Participants must have a recent kidney biopsy showing certain features and stable kidney function.
This study looks at the long-term safety and effectiveness of atacicept in people with IgA nephropathy (IgAN) who have already completed treatment in a previous atacicept study. It is for patients who want to continue their care and see how well the medicine works over more time.
This trial tests if telitacicept can safely help children aged 5–18 with IgA nephropathy or IgA vasculitis nephritis. It aims to reduce protein in the urine and protect kidney function.
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
This trial tests if avacopan, a targeted anti-inflammatory drug, can safely treat a severe form of IgA nephropathy (IgAN) where small crescents form in the kidney filters. It may help reduce protein leakage and preserve kidney function.
This trial tests a medicine called CM313 in people with IgA nephropathy, a kidney disease. It may help reduce protein in the urine, which is a sign of kidney damage.
Hear when a new IgAN trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.